Curioler — home

Understand the research. Trust the ground you're standing on.

Curioler is a knowledge base for caregivers of neurodivergent children — research made easy, fact checks, studies, and real family experiences, each one graded for trust from peer-reviewed evidence through to individual experience. Free to read. No account needed.

It is also where you keep track of your own child. With an account you can note what you see day to day, log sleep and therapy sessions, and talk any of it through with Sunita. She has your child's profile and your recent notes in front of her, and she answers from the same graded research you can read here.

Tier 1–2

Strong research evidence

Peer-reviewed studies and systematic reviews.

Tier 3–4

Clinical consensus

Professional guidance where formal trials are limited.

Tier 5–6

Community experience

Real family accounts — valuable, but individual.

Recently published

  • GeneralSystematic reviewTier 1 · Strong research evidence

    L-carnosine for autistic children: an early promise the later trials did not confirm

    A 2025 systematic review of 20 antioxidant trials in autism found the L-carnosine studies contradictory and at high risk of bias, with no solid evidence of clinical benefit. The individual randomised trials mostly missed their main targets: no change in autism severity or irritability, with scattered improvements in single areas such as sleep quality or hyperactivity that no second trial has confirmed.

    14 September 2026 · 1 readRead full breakdown →
  • GeneralSystematic reviewTier 1 · Strong research evidence

    Autinorm syrup: no trials of the product, and its folate is not the one the research used

    There are no published clinical trials of Autinorm in autistic children — none. The evidence its marketing gestures at belongs to leucovorin (folinic acid), a prescription medicine, and a major review states plainly that folinic acid is the only form of folate used to treat cerebral folate deficiency apart from a single case report. Autinorm contains methylfolate instead, at a dose far below what those studies used, and paediatric bodies say even leucovorin is not standard care for autism.

    14 September 2026Read full breakdown →
  • BehaviourSystematic reviewTier 1 · Strong research evidence

    What risperidone 0.5 mg (sold as Sizodone) does — and does not do — for autistic children

    A meta-analysis of 41 studies found risperidone consistently reduced irritability, hyperactivity, lethargy, inappropriate speech and stereotypic behaviour in autistic children aged 2 to 17, over both short and longer periods. It also found a consistent link with weight gain and increased waist circumference. No study looked at the 0.5 mg dose or the Sizodone brand in isolation — 0.5 mg is simply a common starting or low maintenance dose.

    14 September 2026 · 2 readsRead full breakdown →
  • GeneralClinical consensusTier 3 · Clinical consensus

    When is it time to stop occupational therapy?

    Professional guidelines from AOTA, APTA and ASHA, along with hospital discharge policies, converge on three main reasons to end pediatric therapy: goals are met, therapy is no longer producing functional change, or the family decides to conclude care. Guidelines also describe stepping down to less frequent or consultative therapy rather than stopping outright, and treat therapy as something a child may return to at later stages. None of this comes from controlled trials of when to stop.

    11 September 2026 · 3 readsRead full breakdown →

We're caregiver parents too — we read the studies, grade the evidence, and only publish what we'd want to find ourselves at 2am, searching for answers.